Literature DB >> 7538980

Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity.

L I Brasoveanu1, M Altomonte, A Gloghini, E Fonsatti, S Coral, A Gasparollo, R Montagner, I Cattarossi, C Simonelli, A Cattelan.   

Abstract

Immunohistochemical and/or indirect immunofluorescence analysis with monoclonal antibody (MAb) H19 demonstrated the expression of protectin (CD59) in 54 surgically removed metastatic melanoma lesions and on 8 out of 12 melanoma cell lines. CD59 expression had a low degree of intra- and intertumor heterogeneity. SDS-PAGE analysis showed that the molecular weight of CD59 expressed on melanoma cells is about 20 kDa. Treatment of melanoma cells with 5U/ml of phosphatidylinositol-specific phospholipase C completely abolished cell-surface expression of CD59. Interferon-gamma and/or tumor necrosis factor-alpha or phorbol 12-myristate 13-acetate neither modulated the expression of CD59 by melanoma cells nor influenced the amounts of CD59-specific mRNA. F(ab')2 fragments of anti-CD59 MAb YTH53. I did not inhibit the lysis of melanoma cells by allogeneic natural killer (NK) cells or lymphokine-activated killer (LAK) cells. In contrast, the whole Ig molecule of MAb HI9 or YTH53.I significantly (p < 0.05) enhanced NK-cell-mediated lysis of melanoma cells, suggesting the induction of antibody-dependent cell-mediated cytotoxicity. Lastly, masking of CD59 by MAb YTH53.I or its F(ab')2 fragments significantly (p < 0.05) enhanced, in a dose-dependent fashion, the lysis of anti-GD3-sensitized melanoma cells by homologous complement. These data demonstrate that CD59 expressed by human melanoma cells might regulate host-tumor interaction by protecting neoplastic cells from complement-mediated lysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538980     DOI: 10.1002/ijc.2910610420

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

Authors:  L I Brasoveanu; E Fonsatti; A Visintin; M Pavlovic; I Cattarossi; F Colizzi; A Gasparollo; S Coral; V Horejsi; M Altomonte; M Maio
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.

Authors:  J Yu; T Caragine; S Chen; B P Morgan; A B Frey; S Tomlinson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  Tumour-derived interleukin 1alpha (IL-1alpha) up-regulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) by endothelial cells.

Authors:  E Fonsatti; M Altomonte; S Coral; I Cattarossi; M R Nicotra; A Gasparollo; P G Natali; M Maio
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis.

Authors:  L Bjørge; S Junnikkala; E K Kristoffersen; J Hakulinen; R Matre; S Meri
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas.

Authors:  Enrico Radaelli; Els Hermans; Lorna Omodho; Annick Francis; Sara Vander Borght; Jean-Christophe Marine; Joost van den Oord; Frédéric Amant
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

Review 6.  Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.

Authors:  Zvi Fishelson; Michael Kirschfink
Journal:  Front Immunol       Date:  2019-04-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.